Vardhaman Laboratories Peer Comparison
BSE: 524796
₹0.51
₹0.02
(4.08%)
As on 16-Aug-2019IST
Market cap
₹0 Cr
Revenue (TTM)
₹0 Cr
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
0 %
Edit
| Vardhaman Laboratories | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
0 | 37,857 | 27,713 | 26,763 | 28,045 |
Revenue (₹ Cr) |
-- | 3,564 | 1,936 | 1,462 | 9,205 |
Net Profit (₹ Cr) |
-0.02 | 414.00 | 288.22 | 387.35 | -371.81 |
Net Margin (%) |
-383.33 | 11.23 | 14.79 | 26.01 | -3.93 |
RoE (%) |
-1.15 | 8.38 | 29.77 | 25.18 | -3.85 |
Price to Earnings |
-- | 92.56 | 96.15 | 69.30 | -- |
Price-To-Book |
0.11 | 7.52 | 20.65 | 15.51 | 3.50 |
Income Statement (₹ Cr)
| Vardhaman Laboratories | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 3,936.90 | 65.18 | 188.22 | -- |
|
Total Income
|
0.04 | 4,114.39 | 69.48 | 191.18 | -- |
|
Total Expenditure
|
0.08 | 3,992.33 | 60.56 | 157.70 | -- |
|
EBITDA
|
-0.08 | -55.43 | 4.63 | 30.52 | -- |
|
Depreciation
|
-- | 149.53 | 6.27 | 1.91 | -- |
|
EBIT
|
-0.08 | -204.96 | -1.64 | 28.62 | -- |
|
Interest
|
0.00 | 255.49 | 2.16 | 3.23 | -- |
|
Other Income
|
0.04 | 177.49 | 4.29 | 2.96 | -- |
|
Exceptional Items
|
-- | -358.19 | -- | -- | -- |
|
Profit before Tax
|
-0.04 | -641.15 | 0.49 | 28.35 | -- |
|
Provision for Tax
|
-- | 25.70 | 0.28 | 9.85 | -- |
|
Profit after Tax
|
-0.04 | -666.85 | 0.21 | 18.50 | -- |
Liabilities (₹ Cr)
| Vardhaman Laboratories | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2.00 | 2,852.15 | 178.44 | 57.68 | -- |
|
Minority Interest
|
-- | 345.73 | -- | -- | -- |
|
Non-Current Liabilities
|
0.00 | 2,088.89 | 14.20 | 32.73 | -- |
|
Current Liabilities
|
0.03 | 2,691.71 | 34.62 | 65.00 | -- |
|
Total Liabilities
|
2.03 | 8,127.59 | 227.25 | 155.45 | -- |
Assets (₹ Cr)
| Vardhaman Laboratories | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.00 | 4,598.88 | 73.08 | 66.45 | -- |
|
Current Assets
|
2.03 | 3,379.60 | 154.17 | 87.20 | -- |
|
Total Assets
|
2.03 | 8,127.59 | 227.25 | 155.45 | -- |
|
Total Debt*
|
0.00 | 3,747.82 | 29.82 | 43.83 | -- |
|
Net Current Assets
|
2.00 | 687.89 | 119.55 | 22.19 | -- |
|
Contingent Liabilities
|
-- | 576.12 | -- | -- | -- |
Cashflow (₹ Cr)
| Vardhaman Laboratories | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
0.02 | 68.44 | -16.11 | 8.46 | -- |
|
Cash Flow from Investing Activities
|
-- | 630.24 | 19.72 | -25.32 | -- |
|
Cash from Financing Activities
|
-0.08 | -769.47 | -2.53 | 14.62 | -- |
|
Net Cash Inflow / Outflow
|
-0.06 | -70.79 | 1.08 | -2.23 | -- |
Ratios
Profitability Ratios
| Vardhaman Laboratories | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-1.98 | -5.47 | 1.27 | 38.24 | -- |
|
ROE (%)
|
-1.98 | -21.81 | 0.12 | 39.03 | -- |
|
ROA (%)
|
-1.96 | -7.93 | 0.09 | 13.99 | -- |
|
EBIT Margin (%)
|
-- | 3.10 | 13.68 | 17.79 | -- |
|
Net Margin (%)
|
-113.14 | -16.21 | 0.31 | 9.67 | -- |
|
Cash Profit Margin (%)
|
-- | -13.14 | 9.94 | 10.84 | -- |
Growth Ratios
| Vardhaman Laboratories | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | -1.94 | 0.00 | 17.45 | -- |
|
EBIT Growth (%)
|
-10.63 | -3.93 | -8.67 | 43.40 | -- |
|
Net Profit Growth (%)
|
-7.75 | -195.01 | 0.00 | 53.51 | -- |
|
EPS Growth (%)
|
-7.79 | -210.52 | 0.00 | 54.05 | -- |
|
Book Value Growth (%)
|
-1.97 | -14.68 | 0.00 | 43.84 | -- |
Valuation Ratios
| Vardhaman Laboratories | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 0.00 | 0.00 | 0.00 | -- |
|
Price / Book Value
|
0.14 | 2.85 | 0.00 | 0.00 | -- |
|
Dividend Yield (%)
|
0.00 | 0.00 | -- | -- | -- |
|
EV/EBITDA
|
3.82 | 87.67 | 3.50 | 1.32 | -- |
|
Market Cap (₹ Cr)
|
-- | 8,035.78 | 0.00 | 0.00 | -- |
Solvency Ratios
| Vardhaman Laboratories | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 1.33 | 0.17 | 0.78 | -- |
|
Short term debt to equity ratio
|
-- | 0.15 | 0.08 | 0.16 | -- |
|
Current Ratio
|
70.12 | 1.26 | 4.45 | 1.34 | -- |
|
Quick Ratio
|
70.12 | 0.94 | 4.05 | 0.92 | -- |
|
Interest Coverage
|
-1,740.70 | -1.51 | 1.23 | 9.79 | -- |
Operating Efficiency Ratios
| Vardhaman Laboratories | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 24.45 | 57.13 | 26.55 | -- |
|
Asset Turnover
|
0.00 | 0.47 | 0.29 | 1.42 | -- |
|
Receivable days
|
-- | 92.57 | 208.51 | 83.83 | -- |
|
Inventory Days
|
-- | 91.03 | 78.67 | 45.68 | -- |
|
Payable days
|
-- | 115.29 | 264.75 | 139.26 | -- |
|
Cash Conversion Cycle
|
-- | 68.30 | 22.43 | -9.76 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
